Joustra Wouter 4

What Happened

• Wouter Joustra, a director of Vor Biopharma (VOR), was granted a derivative award covering 57,162 shares on 2026-06-11. The transaction is reported as an award/grant (code A) with a reported acquisition price of $0.00 and total reported value of $0. This is a compensation equity award (an option grant), not an open-market purchase or sale.

Key Details

• Transaction date: 2026-06-11; Form 4 filed: 2026-06-12 (timely).
• Reported shares/units granted: 57,162 (derivative securities). Reported price: $0.00; reported value: $0.
• Shares owned after the transaction: Not disclosed in the filing.
• Footnote: One thirty-sixth of the shares subject to the option vest and become exercisable on July 11, 2026 and each month thereafter, subject to continued service (i.e., 36 monthly installments starting 07/11/2026).
• No exercise price or immediate cashless sale is disclosed in the Form 4.

Context

• This was an option/award grant as part of compensation. Such grants vest over time and only become exercisable according to the stated schedule; they do not represent an immediate purchase of shares or a sale. Because the exercise price and total potential dilution/value are not provided in this filing, you cannot infer the award's monetary worth from the Form 4 alone.